CoVP CommunicationsThis page contains COVID-19 Vaccine communications sent out from the Connecticut Department of Public Health Immunization Program.
If you would like to sign up to receive these communications directly, please send an email to Dph.email@example.com with the subject line “Subscribe to COVID-19 Program communications”.
- Pfizer BLA, Novavax EUA, Fall Booster Updates July 20, 2022 7/20/22
- Slides from the COVID-19 Vaccine Provider Update Call for July 6, 2022 7/6/22
- Moderna expansion for children 6 through 17 years of age 6/27/22
- Young Pediatric Vaccine Provider Webinars 6/21/22
- COVID-19 Vaccine Recommendation Expanded to Children 6 months through 4 Years of Age, June 19, 2022 6/19/22
- Slides from the COVID-19 Vaccine Provider Update Call for June 1 2022 6/1/22
- [Urgent] Action Required: Pre-ordering for COVID-19 Vaccine for Children Age 6 months through 5 years - Week 1 5/31/22
- COVID-19 Vaccine Provider Update on Pediatric (under 5) Roll out and Planning 5/26/22
- 5.24.22 Summer Provider Survey: COVID-19 Ages 0-4 Vaccination Planning 5/24/22
- Expanded COVID-19 Booster Recommendation to Children 5-11 Years of Age, May 19, 2022 5/19/22
- CDC COCA Call: Clinical Recommendations for Adenovirus Testing and Reporting of Children with Acute Hepatitis of Unknown Etiology - May 19, 2022, 2:00 PM – 3:00 PM ET 5/12/22
- CDC HAN: Updated Recommendations for Adenovirus Testing and Reporting of Children with Acute Hepatitis of Unknown Etiology 5/11/22
- FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals May 6, 2022 5/6/22
- Slides from the COVID-19 Vaccine Provider Update Call for May 4, 2022 5/4/22
- COVID-19 Vaccine Pediatric (age 4 and under) Anticipated Roll out and Program Updates May 3, 2022 5/3/22
- CDC Health Alert Network (HAN) Health Advisory 463: Updated Information on Availability and Use of Treatments for Outpatients with Mild to Moderate COVID-19 Who are at Increased Risk for Severe Outcomes of COVID-19 4/25/22
- Slides from the COVID-19 Vaccine Provider Update Call for April 6, 2022 4/6/22
- COVID-19 Interim Clinical Considerations Updated and Moderna Product Clarification 4/4/22
Click here to review previously published CoVP Communications.